These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20144636)

  • 1. A physiologically based biodynamic (PBBD) model for estragole DNA binding in rat liver based on in vitro kinetic data and estragole DNA adduct formation in primary hepatocytes.
    Paini A; Punt A; Viton F; Scholz G; Delatour T; Marin-Kuan M; Schilter B; van Bladeren PJ; Rietjens IM
    Toxicol Appl Pharmacol; 2010 May; 245(1):57-66. PubMed ID: 20144636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of nevadensin as an important herb-based constituent inhibiting estragole bioactivation and physiology-based biokinetic modeling of its possible in vivo effect.
    Alhusainy W; Paini A; Punt A; Louisse J; Spenkelink A; Vervoort J; Delatour T; Scholz G; Schilter B; Adams T; van Bladeren PJ; Rietjens IM
    Toxicol Appl Pharmacol; 2010 Jun; 245(2):179-90. PubMed ID: 20226806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo validation of DNA adduct formation by estragole in rats predicted by physiologically based biodynamic modelling.
    Paini A; Punt A; Scholz G; Gremaud E; Spenkelink B; Alink G; Schilter B; van Bladeren PJ; Rietjens IM
    Mutagenesis; 2012 Nov; 27(6):653-63. PubMed ID: 22844077
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A physiologically based biokinetic (PBBK) model for estragole bioactivation and detoxification in rat.
    Punt A; Freidig AP; Delatour T; Scholz G; Boersma MG; Schilter B; van Bladeren PJ; Rietjens IM
    Toxicol Appl Pharmacol; 2008 Sep; 231(2):248-59. PubMed ID: 18539307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo validation and physiologically based biokinetic modeling of the inhibition of SULT-mediated estragole DNA adduct formation in the liver of male Sprague-Dawley rats by the basil flavonoid nevadensin.
    Alhusainy W; Paini A; van den Berg JH; Punt A; Scholz G; Schilter B; van Bladeren PJ; Taylor S; Adams TB; Rietjens IM
    Mol Nutr Food Res; 2013 Nov; 57(11):1969-78. PubMed ID: 23894034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico methods for physiologically based biokinetic models describing bioactivation and detoxification of coumarin and estragole: implications for risk assessment.
    Rietjens IM; Punt A; Schilter B; Scholz G; Delatour T; van Bladeren PJ
    Mol Nutr Food Res; 2010 Feb; 54(2):195-207. PubMed ID: 19943261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats.
    Punt A; Paini A; Boersma MG; Freidig AP; Delatour T; Scholz G; Schilter B; van Bladeren PJ; Rietjens IM
    Toxicol Sci; 2009 Aug; 110(2):255-69. PubMed ID: 19447879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunochemical identification of hepatic protein adducts derived from estragole.
    Wakazono H; Gardner I; Eliasson E; Coughtrie MW; Kenna JG; Caldwell J
    Chem Res Toxicol; 1998 Aug; 11(8):863-72. PubMed ID: 9705747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Physiologically based biokinetic (PBBK) model for safrole bioactivation and detoxification in rats.
    Martati E; Boersma MG; Spenkelink A; Khadka DB; Punt A; Vervoort J; van Bladeren PJ; Rietjens IM
    Chem Res Toxicol; 2011 Jun; 24(6):818-34. PubMed ID: 21446753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of human interindividual variation in bioactivation of estragole using physiologically based biokinetic modeling.
    Punt A; Jeurissen SM; Boersma MG; Delatour T; Scholz G; Schilter B; van Bladeren PJ; Rietjens IM
    Toxicol Sci; 2010 Feb; 113(2):337-48. PubMed ID: 19920071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estragole: DNA adduct formation in primary rat hepatocytes and genotoxic potential in HepG2-CYP1A2 cells.
    Schulte-Hubbert R; Küpper JH; Thomas AD; Schrenk D
    Toxicology; 2020 Nov; 444():152566. PubMed ID: 32853702
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of Interindividual Human Variation in Bioactivation and DNA Adduct Formation of Estragole in Liver Predicted by Physiologically Based Kinetic/Dynamic and Monte Carlo Modeling.
    Punt A; Paini A; Spenkelink A; Scholz G; Schilter B; van Bladeren PJ; Rietjens IM
    Chem Res Toxicol; 2016 Apr; 29(4):659-68. PubMed ID: 26952143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix modulation of the bioactivation of estragole by constituents of different alkenylbenzene-containing herbs and spices and physiologically based biokinetic modeling of possible in vivo effects.
    Alhusainy W; van den Berg SJ; Paini A; Campana A; Asselman M; Spenkelink A; Punt A; Scholz G; Schilter B; Adams TB; van Bladeren PJ; Rietjens IM
    Toxicol Sci; 2012 Sep; 129(1):174-87. PubMed ID: 22649189
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA adduct formation and T lymphocyte mutation induction in F344 rats implanted with tumorigenic doses of 1,6-dinitropyrene.
    Beland FA
    Res Rep Health Eff Inst; 1995 Oct; (72):1-27; discussion 29-39. PubMed ID: 11381742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aflatoxin-albumin adducts: a basis for comparative carcinogenesis between animals and humans.
    Wild CP; Hasegawa R; Barraud L; Chutimataewin S; Chapot B; Ito N; Montesano R
    Cancer Epidemiol Biomarkers Prev; 1996 Mar; 5(3):179-89. PubMed ID: 8833618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular levels and molecular dynamics simulations of estragole DNA adducts point at inefficient repair resulting from limited distortion of the double-stranded DNA helix.
    Yang S; Diem M; Liu JDH; Wesseling S; Vervoort J; Oostenbrink C; Rietjens IMCM
    Arch Toxicol; 2020 Apr; 94(4):1349-1365. PubMed ID: 32185416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NTP technical report on the toxicity and metabolism studies of chloral hydrate (CAS No. 302-17-0). Administered by gavage to F344/N rats and B6C3F1 mice.
    Beland FA
    Toxic Rep Ser; 1999 Aug; (59):1-66, A1-E7. PubMed ID: 11803702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantitative comparison between in vivo DNA adduct formation from exposure to selected DNA-reactive carcinogens, natural background levels of DNA adduct formation and tumour incidence in rodent bioassays.
    Paini A; Scholz G; Marin-Kuan M; Schilter B; O'Brien J; van Bladeren PJ; Rietjens IM
    Mutagenesis; 2011 Sep; 26(5):605-18. PubMed ID: 21642616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genotoxicity of 1,3-butadiene and its epoxy intermediates.
    Walker VE; Walker DM; Meng Q; McDonald JD; Scott BR; Seilkop SK; Claffey DJ; Upton PB; Powley MW; Swenberg JA; Henderson RF;
    Res Rep Health Eff Inst; 2009 Aug; (144):3-79. PubMed ID: 20017413
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular dosimetry and repair of N(2),3-ethenoguanine in rats exposed to vinyl chloride.
    Morinello EJ; Ham AJ; Ranasinghe A; Nakamura J; Upton PB; Swenberg JA
    Cancer Res; 2002 Sep; 62(18):5189-95. PubMed ID: 12234983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.